Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease
Open Access
- 1 June 2023
- journal article
- research article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 12 (6) , e220215
Abstract
Aim: Herein, we report safety outcomes for varenicline solution nasal spray (VNS) within the context of clinical trial discontinuation, contrasting those with discontinuation outcomes from topical cyclosporine and lifitegrast clinical trials. Materials & methods: 1061 subjects were randomized across three clinical trials to receive either VNS 0.06 mg, VNS 0.03 mg, VNS 0.006 mg or vehicle control. Subjects who discontinued from treatment were noted and assigned to their appropriate categories. Results: Despite treatment emergent adverse events, 93.5% of subjects receiving VNS completed the treatment period. By comparison, only 80% of subjects in the integrated clinical trials for cyclosporine ophthalmic emulsion and 91% of subjects in the integrated trials for lifitegrast ophthalmic solution completed the full treatment period, respectively. Conclusion: In clinical trials, VNS demonstrated improvements in dry eye disease signs and symptoms, was well-tolerated, and had an overall completion rate >93%. Conventional dry eye treatments (e.g., cyclosporine and lifitegrast) noted considerably higher discontinuation rates in their clinical trials.Keywords
This publication has 26 references indexed in Scilit:
- Difficulty in eye drop administration for people with rheumatoid arthritisBritish Journal of Occupational Therapy, 2016
- Associations between signs and symptoms of dry eye disease: a systematic reviewClinical Ophthalmology, 2015
- The psychological impact of eyedrops administration in childrenJournal of American Association for Pediatric Ophthalmology and Strabismus, 2015
- Evaluation of eyedrop administration by inexperienced patients after cataract surgeryJournal of Cataract & Refractive Surgery, 2014
- Dry Eye in the Beaver Dam Offspring Study: Prevalence, Risk Factors, and Health-Related Quality of LifeAmerican Journal of Ophthalmology, 2014
- Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey StriatumThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic ReceptorsMolecular Pharmacology, 2006
- The Lack of Association Between Signs and Symptoms in Patients With Dry Eye DiseaseCornea, 2004
- The Effect of Punctal Occlusion on Tear Lactoferrin in Aqueous Deficient Dry Eye Patients2002
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease11Reprint requests to: Linda Lewis, 575 Anton Blvd, Suite 900, Costa Mesa, CA 92626.Ophthalmology, 2000